CARLOS SALGUEIRO: Open Payments
NPI 1407914039 · WESTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,017 in 195 payments from 18 companies in 2025. Trend: 2023 $2,123 · 2024 $2,539 · 2025 $5,017
Food & beverage: $5,017
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $963 |
| Teva Pharmaceuticals USA, Inc. | 35 | $871 |
| Alkermes, Inc. | 29 | $589 |
| Janssen Pharmaceuticals, Inc | 15 | $376 |
| Corium, LLC | 13 | $362 |
| Otsuka America Pharmaceutical, Inc. | 13 | $331 |
| Neurocrine BioSciences, Inc. | 6 | $256 |
| Supernus Pharmaceuticals, Inc. | 8 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $164 |
| E.R. Squibb & Sons, L.L.C. | 7 | $157 |
Products named: CAPLYTA, ARISTADA, UZEDY, AUSTEDO XR, Azstarys, INVEGA SUSTENNA, REXULTI, INGREZZA.
Industry payments across FL — which companies pay providers there.
